Ticker

TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“COSCIENS” or the “Company”) today reported its financial and operating results for the second quarter ended June 30, 2026. All amounts in this press release are in U.S. dollars.

TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), today announced the previously announced consolidation (the “Consolidation”) of the common shares of the Company (the “Common Shares”) on the basis of a ratio of one post-Consolidation Common Share for every 150 pre-Consolidation Common Shares (the “Consolidation Ratio”); and (ii) an…

TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), today announced the previously announced consolidation (the "Consolidation") of the common shares of the Company (the "Common Shares") on the basis of a ratio of one post-Consolidation Common Share for every 150 pre-Consolidation Common Shares (the "Consolidation Ratio"); and (ii) an…

TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the next steps in connection with changes to the Company's share capital (the “Share Capital Amendment”).

TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") announced the next steps in connection with changes to the Company's share capital (the "Share Capital Amendment"). The Share Capital Amendment was approved at the Company's annual general and special meeting of shareholders held on June 17, 2026.